PURE Bioscience Reports 2013 Fiscal First Quarter Financial Results Business Wire SAN DIEGO -- December 12, 2012 PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2012. Revenues for the fiscal first quarter of 2013 were $110,000, compared with revenues of $257,000 for the fiscal first quarter of 2012. Total operating costs and expenses for the fiscal first quarter of 2013 were $1.9 million, a decrease of $700,000 compared to fiscal first quarter 2012 operating costs and expenses of $2.6 million. The loss from operations for the fiscal first quarter of 2013 was $1.8 million, a decrease of $600,000 compared to the fiscal first quarter 2012 loss from operations of $2.4 million. The net loss for the fiscal first quarter of 2013 was $2.2 million or $0.25 per share, compared with a net loss of $2.4 million, or $0.47 per share, in the fiscal first quarter of 2012. During the 2013 fiscal first quarter, the Company completed an underwritten public equity offering resulting in net proceeds of approximately $4.2 million, providing funds to extinguish bridge loan debt of approximately $1.3 million and for future working capital. As of October 31, 2012, the Company had cash and cash equivalents of approximately $2.5 million. “The fiscal first quarter of 2013 was a transition quarter in which we successfully completed our plan to maintain our NASDAQ Capital Market listing by completing a reverse stock split and closing the public equity offering,” said Michael L. Krall, President and CEO of PURE Bioscience. “Looking ahead to calendar year 2013, we are focused on executing on our business plan to commercialize the PURE technology into various channels in the market place, including potential use in food service and food processing facilities and also in medical and educational facilities.” About PURE Bioscience, Inc. PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its proposed initiatives and business plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Pure Bioscience, Inc. Consolidated Balance Sheets October 31, July 31, 2012 2012 (Unaudited) Assets Current assets Cash and cash equivalents $ 2,450,000 $ 877,000 Accounts receivable, net 64,000 373,000 Inventories, net 864,000 654,000 Prepaid expenses 80,000 347,000 Total current assets 3,458,000 2,251,000 Property, plant and equipment, net 226,000 257,000 Patents, net 1,988,000 1,950,000 Total assets $ 5,672,000 $ 4,458,000 Liabilities and stockholders' equity Current liabilities Accounts payable $ 2,094,000 $ 1,946,000 Loan payable, net - 962,000 Deferred revenue - 66,000 Accrued liabilities 405,000 344,000 Derivative liability 91,000 319,000 Total current liabilities 2,590,000 3,637,000 Deferred rent 3,000 3,000 Total liabilities 2,593,000 3,640,000 Commitments and contingencies Stockholders' equity Preferred stock, $0.01 par value: 5,000,000 shares authorized, no - - shares issued Common stock, $0.01 par value: 100,000,000 shares authorized 10,986,170 issued and outstanding at October 31, 2012, and 6,644,555 issued and outstanding at 110,000 67,000 July 31, 2012. Additional paid-in capital 67,623,000 63,251,000 Accumulated deficit (64,654,000 ) (62,500,000 ) Total stockholders' equity 3,079,000 818,000 Total liabilities and stockholders' $ 5,672,000 $ 4,458,000 equity Pure Bioscience, Inc. Consolidated Statements of Operations (Unaudited) Three months ended October 31, 2012 2011 Net product sales $ 110,000 $ 257,000 Operating costs and expenses Cost of goods sold 31,000 129,000 Selling, general and administrative 1,476,000 1,997,000 Research and development 395,000 493,000 Total operating costs and expenses 1,902,000 2,619,000 Loss from operations (1,792,000 ) (2,362,000 ) Other income (expense) Change in derivative liability 228,000 - Interest expense (588,000 ) - Interest income - 1,000 Other (expense) income, net (2,000 ) - Total other (expense) income (362,000 ) 1,000 Net loss $ (2,154,000 ) $ (2,361,000 ) Basic and diluted net loss per share $ (0.25 ) $ (0.47 ) Shares used in computing basic and diluted net loss per share 8,720,980 5,044,950 Contact: PURE Bioscience Investor Contact: LHA Don Markley, Senior Vice President (310) 691-7100 firstname.lastname@example.org
PURE Bioscience Reports 2013 Fiscal First Quarter Financial Results
Press spacebar to pause and continue. Press esc to stop.